All Journals > The Journal of Infectious Diseases > 1 July 2007 > Current TB/HIV Clinical Trials

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

Science Watch logo

JID Article Named "New Hot Paper" by ScienceWatch.com

Dr. Lauri Hicks' 2007 article on pneumococcal disease has been named a "hot new paper" by Thompson Reuters' ScienceWatch.com. Read a Q&A about the article with Dr. Hicks here. 

Press Release

Unique Collaboration Charts the Migrations of a Parasite that Affected History
Researchers Sequence Louse DNA from Mummies and Propose New Model for its Development


In the News

Featured in Grist
"Another symptom of swine flu: instant amnesia" May 11, 2009
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Read the veterinary literature on swine flu and you get a strong sense of what might be called vaccination treadmill: the hog industry is literally scrambling to generate new vaccines for the rapidly evolving flu strains that sweep through CAFOs. Writing in the Journal of Infectious Diseases [PDF] in 2008, Eileen Thacker and Bruce Janke of Iowa State University paint a stark picture: “A number of genetically diverse viruses are circulating in swine herds throughout the world and are a major cause of concern to the swine industry,” they write. “Influenza virus infections in swine and poultry are potential sources of viruses for the next pandemic among humans.”

Featured in New York Times
"Fear of a Swine Flu Epidemic in 1976 Offers Some Lessons, and Concerns, Today" May 8, 2009
Anti‐Ganglioside Antibody Induction by Swine (A/NJ/1976/H1N1) and Other Influenza Vaccines: Insights into Vaccine‐Associated Guillain‐Barré Syndrome
Irving Nachamkin, Sean V. Shadomy, Anthony P. Moran, Nancy Cox, Collette Fitzgerald, Huong Ung, Adrian T. Corcoran, John K. Iskander, Lawrence B. Schonberger, and Robert T. Chen
Irving Nachamkin, a professor of pathology and laboratory medicine at the University of Pennsylvania, examined some 1976 vaccine that had been saved by a scientist in Texas. In a paper published last year in The Journal of Infectious Diseases, he and colleagues reported that mice given the vaccine made antibodies that reacted with gangliosides, which are components of nerve cells. An antibody attack on gangliosides is part of the disease mechanism of Guillain-Barré.

Featured in AFP
"Swine flu vaccine 'could be ready soon'" May 7, 2009
A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses
Mary A. Hoelscher, Neetu Singh, Sanjay Garg, Lakshmi Jayashankar, Vic Veguilla, Aseem Pandey, Yumi Matsuoka, Jacqueline M. Katz, Ruben Donis, Suresh K. Mittal, and Suryaprakash Sambhara
The vaccine Mittal created for the bird flu worked on three different strains isolated over a seven-year period and was described in papers for the Journal of Infectious Diseases and the journal Clinical Pharmacology and Therapeutics.

Featured in Newsweek
"The Path of a Pandemic" http://www.newsweek.com/id/195692
Swine Influenza Virus: Zoonotic Potential and Vaccination Strategies for the Control of Avian and Swine Influenzas
Eileen Thacker and Bruce Janke
Last year researchers from Iowa State University in Ames warned that pigs located in industrial-scale farms were being subjected to influenza infections from farm poultry, wild birds and their human handlers. Writing in The Journal of Infectious Diseases, Eileen Thacker and Bruce Janke said, "As a result of the constantly changing genetic makeup of individual influenza viruses in pigs, the U.S. swine industry is continually scrambling to respond to the influenza viruses circulating within individual production systems."

1 July 2007 Supplement

Volume 196, Number S1
The Journal of Infectious Diseases 2007;196:S46–S51
© 2007 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2007/19604S1-0007$15.00
DOI: 10.1086/518658
SUPPLEMENT ARTICLE

Treatment Strategies for HIV‐Infected Patients with Tuberculosis: Ongoing and Planned Clinical Trials

François‐Xavier Blanc,1,2

Diane V. Havlir,3

Philip C. Onyebujoh,5

Sok Thim,6

Anne E. Goldfeld,4,6 and

Jean‐François Delfraissy1,2

1Agence Nationale de Recherches sur le Sida et les Hépatites Virales, Paris, and 2Assistance Publique–Hôpitaux de Paris, Service de Médecine Interne, Centre Hospitalier Universitaire de Bicêtre, Paris XI University, Le Kremlin‐Bicêtre, France; 3San Francisco General Hospital, University of California, San Francisco, California, and 4CBR Institute for Biomedical Research, Harvard Medical School, Boston, Massachusetts; 5United Nations Children's Fund/United Nations Development Programme/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland; 6Cambodian Health Committee, Phnom Penh, Cambodia

Currently, there are limited data to guide the management of highly active antiretroviral therapy (HAART) for human immunodeficiency virus type 1 (HIV‐1)–infected patients with active tuberculosis (TB), the leading cause of death among individuals with acquired immunodeficiency syndrome (AIDS) in resource‐limited areas. Four trials to take place in Southeast Asian, African, and South American countries will address the unresolved question of the optimal timing for initiation of HAART in patients with AIDS and TB: (1) Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA [ANRS 1295/NIH‐CIPRA KH001]), (2) Adult AIDS Clinical Trials Group A5221, (3) START, and (4) a trial sponsored by the World Health Organization/Special Programme for Research and Training in Tropical Diseases. Two other clinical questions regarding patients with TB and HIV‐1 coinfection are also undergoing evaluation: (1) the benefits of short‐term HAART when CD4 cell counts are >350 cells/mm3 (PART [NIH 1 R01 AI051219‐01A2]) and (2) the efficacy of a once‐daily HAART regimen in treatment‐naive patients (BKVIR [ANRS 129]). Here, we present an overview of these ongoing or planned clinical studies, which are supported by international agencies.

Reprints or correspondence: Dr. François‐Xavier Blanc, Service de Médecine Interne, Centre Hospitalier Universitaire de Bicêtre, 78 rue du Général Leclerc, F‐94275 Le Kremlin Bicêtre, France ().

Cited by

Stephen D Lawn, Gavin Churchyard. (2009) Epidemiology of HIV-associated tuberculosis. Current Opinion in HIV and AIDS 4:4, 325-333
Online publication date: 1-Aug-2009.
CrossRef
Umesh G. Lalloo. (2009) Editorial Commentary: Efavirenz and Nevirapine Interactions with Rifampicin: Resolving the Dilemmas?. Clinical Infectious Diseases 48:12, 1760-1762
Online publication date: 15-Jun-2009.
Citation-Full Text-PDF Version (164 kB)
Neel R Gandhi, Anthony P Moll, Umesh Lalloo, Robert Pawinski, Kimberly Zeller, Pravi Moodley, Eugene Meyer, Gerald Friedland. (2009) Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: The Sizonqoba Study. JAIDS Journal of Acquired Immune Deficiency Syndromes 50:1, 37-43
Online publication date: 1-Feb-2009.
CrossRef
Beatriz Manzor Mitrzyk. (2008) Treatment of Extensively Drug-Resistant Tuberculosis and Role of the Pharmacist. Pharmacotherapy 28:10, 1243-1254
Online publication date: 1-Nov-2008.
CrossRef
Stephen D Lawn, Anthony D Harries, Xavier Anglaret, Landon Myer, Robin Wood. (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22:15, 1897-1908
Online publication date: 1-Nov-2008.
CrossRef
Graeme Meintjes, Lut Lynen. (2008) Prevention and treatment of the immune reconstitution inflammatory syndrome. Current Opinion in HIV and AIDS 3:4, 468-476
Online publication date: 1-Aug-2008.
CrossRef
Stephen D Lawn, Marc C Lipman, Philippa J Easterbrook. (2008) Immune reconstitution disease associated with mycobacterial infections. Current Opinion in HIV and AIDS 3:4, 425-431
Online publication date: 1-Aug-2008.
CrossRef
Stephen D Lawn, David J Edwards, Robin Wood. (2007) Concurrent drug therapy for tuberculosis and HIV infection in resource-limited settings: present status and future prospects. Future HIV Therapy 1:4, 387-398
Online publication date: 1-Dec-2007.
CrossRef
Gerald Friedland, Gavin J. Churchyard, and Edward Nardell. (2007) Introduction: Tuberculosis and HIV Coinfection: Current State of Knowledge and Research Priorities. The Journal of Infectious Diseases 196:s1, S1-S3
Online publication date: 1-Jul-2007.
Citation-Full Text-PDF Version (183 kB)
Philip Chukwuka Onyebujoh, Isabela Ribeiro, and Christopher Curtis Whalen. (2007) Treatment Options for HIV‐Associated Tuberculosis. The Journal of Infectious Diseases 196:s1, S35-S45
Online publication date: 1-Jul-2007.
Abstract-Full Text-PDF Version (281 kB)

  • Potential conflicts of interest: J.‐F.D. is a member of the advisory boards of Roche, Abbott, and Tibotec. All other authors report no potential conflicts.

    Financial support: Agence Nationale de Recherches sur le Sida et les Hépatites Virales (grant 1295 to F.‐X.B. and J.‐F.D.); Comprehensive International Program of Research on AIDS (grant U01‐KH001 to S.T. and A.E.G.). Supplement sponsorship is detailed in the Acknowledgments.

Back to Top
Close Popup